
July 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX:
ALTERITY THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ATH434 IN MULTIPLE SYSTEM ATROPHY
ALTERITY THERAPEUTICS LTD - ATH434 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE
ALTERITY THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS REPORTED FOR ATH434
ALTERITY THERAPEUTICS LTD - ATH434 SHOWS CLINICAL BENEFIT AND STABILIZES SYMPTOMS